Direct renin inhibition with aliskiren in hypertension and target organ damage.
about
Combination therapy with paricalcitol and trandolapril reduces renal fibrosis in obstructive nephropathyAliskiren: the first renin inhibitor for clinical treatmentAliskiren prevents the toxic effects of peritoneal dialysis fluids during chronic dialysis in ratsAliskiren and valsartan mediate left ventricular remodeling post-myocardial infarction in mice through MMP-9 effects.Therapeutic effects of vitamin D analogs on cardiac hypertrophy in spontaneously hypertensive rats.Aliskiren for the treatment of essential hypertension under real-life practice conditions: design and baseline data of the prospective 3A registry.Antiproteinuric effect of add-on paricalcitol in CKD patients under maximal tolerated inhibition of renin-angiotensin system: a prospective observational study.Multiple genes of the renin-angiotensin system are novel targets of Wnt/β-catenin signaling.Mesenchymal Stromal Cells Prevent Renal Fibrosis in a Rat Model of Unilateral Ureteral Obstruction by Suppressing the Renin-Angiotensin System via HuR.Molecular mechanism of vitamin D in the cardiovascular systemCombination therapy with AT1 blocker and vitamin D analog markedly ameliorates diabetic nephropathy: blockade of compensatory renin increase.Aliskiren, the future of renin-angiotensin system blockade?Aliskiren-hydrochlorothiazide combination for the treatment of hypertension.The Renin Academy Summit: advancing the understanding of renin science.Long-term therapeutic effect of vitamin D analog doxercalciferol on diabetic nephropathy: strong synergism with AT1 receptor antagonist.On target to dual block RAS?New therapeutic agents in diabetic nephropathy.Angiotensin AT1-receptor blockers and cerebrovascular protection: do they actually have a cutting edge over angiotensin-converting enzyme inhibitors?Blocking the RAAS at different levels: an update on the use of the direct renin inhibitors alone and in combination.Direct renin inhibition: from pharmacological innovation to novel therapeutic opportunities.Renin inhibition in the treatment of diabetic kidney disease.The putative (pro)renin receptor blocker HRP fails to prevent (pro)renin signaling.Effect of Multiple-Dose Diltiazem on the Pharmacokinetics of the Renin Inhibitor ACT-077825.Successful treatment of hypertension in anuric hemodialysis patients with a direct Renin inhibitor, aliskiren.A reduction of unilateral ureteral obstruction-induced renal fibrosis by a therapy combining valsartan with aliskiren.Effectiveness and safety of aliskiren and aliskiren hydrochlorothiazide (HCT) in a multiethnic, real-world setting.Maternal caffeine administration leads to adverse effects on adult mice offspring.Tocotrienol is a cardioprotective agent against ageing-associated cardiovascular disease and its associated morbidities.Anti-stress and nootropic activity of drugs affecting the renin-angiotensin system in rats based on indirect biochemical evidence.Disruption of muscle renin-angiotensin system in AT1a-/- mice enhances muscle function despite reducing muscle mass but compromises repair after injury.Two-Year Outcomes of Patients Treated With Aliskiren Under Clinical Practice Conditions: Non-Interventional Prospective Study.Renoprotective effects of the direct renin inhibitor aliskiren on gentamicin-induced nephrotoxicity in rats.Effect of combination therapy with angiotensin receptor blocker and 1,25-dihydroxyvitamin D(3) in type 2 diabetic nephropathy in KK-A(y)/Ta mice.Intervention using vitamin D for elevated urinary albumin in type 2 diabetes mellitus (IDEAL-2 Study): study protocol for a randomised controlled trial.Renin-angiotensin inhibitors reprogram tumor immune microenvironment: A comprehensive view of the influences on anti-tumor immunity
P2860
Q28258849-01DAE669-F899-4933-A572-61BB082951E5Q28272666-2552876A-5D83-455F-B1AE-0D3D4C4C3CF8Q28730295-841912E4-AAC5-4E99-BAAC-56AD7C0C927CQ33893825-021DB76B-2ABE-4446-A199-51B5DD1EEBE3Q34032089-67A8B4A9-CB89-473D-B9D3-F51AB4B89703Q34155229-831060E7-3F0A-45B3-9DA1-A0074975396BQ34483554-52AC9DB1-2476-46EA-B66D-667B7318B0BCQ34787805-4A2B2A04-48E7-4D44-9368-AABC9C476B4AQ35920540-EB8773A3-86E6-4419-8152-B2133638EBCCQ36821166-C8417A12-64B3-4F86-8DEE-AA43E8E350A3Q36924964-991E6512-4DCF-4DC0-8D15-8BFEA6E05F00Q36941829-F5F37522-B815-4FE8-AFDC-6723EDD8D45DQ37104856-FADBF776-CF8E-4191-8F40-8D2A9A931078Q37201622-CBD4EF38-A5CC-4E70-87C1-8202ED60D086Q37337349-C6BE41CF-9609-40A7-A75B-0A00ED5DDFC5Q37368669-56FB3F0A-5873-4C4F-80ED-16807E89FC28Q37559164-90FBF41E-FEC3-4B5B-84D8-49EB5CF70B95Q37600856-09973258-39F7-4292-B4F7-F4AB843EB2C6Q37781702-B9A62F38-9659-42D0-819D-B2ACF3C71DA1Q37939271-B08CAD80-9B96-4908-BA91-B80589AA8B07Q38075571-EAC52394-9790-4A3A-B4B3-0E7C5B24807CQ38571062-69715C96-AC3F-4B7E-8276-F1D2F1856935Q39816378-85F83D2D-4783-45B8-9B52-C8061A8D6683Q41771386-F43B480E-11BE-4130-AC4E-564F42E3DDD3Q42946276-71FCF067-B164-49B5-9AB8-178DB007C195Q43761552-B3E4624E-33F9-492F-BA92-7E48C47C709CQ45751820-553069CA-BE44-4F9C-ABCA-3088C4DEA67EQ48129928-9712EC84-F306-403C-A253-6E5129946BF6Q50690842-988C982F-9877-4471-9D52-00697348AC4EQ52626168-02739F2B-ADEC-49E8-A9AC-1783B08081B6Q52860398-CF71FEA7-5C93-43AD-9285-9C3F31623B7AQ54271513-45B98052-E9C2-4678-BF55-5DB38CE653ADQ54642763-7FC74738-73D2-4ED8-9697-A770AB5E64F0Q55279033-0A3288DD-9D3E-4D27-BD4D-7668F070244AQ59125636-23CC2FC7-7F0D-43FF-A90C-7AF3A6E95C83
P2860
Direct renin inhibition with aliskiren in hypertension and target organ damage.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Direct renin inhibition with aliskiren in hypertension and target organ damage.
@en
type
label
Direct renin inhibition with aliskiren in hypertension and target organ damage.
@en
prefLabel
Direct renin inhibition with aliskiren in hypertension and target organ damage.
@en
P356
P1476
Direct renin inhibition with aliskiren in hypertension and target organ damage.
@en
P2093
Dominik N Müller
P304
P356
10.2215/CJN.01201005
P577
2005-12-22T00:00:00Z